

UNITED THERAPEUTICS CORP

Form 8-K

May 13, 2003

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 13, 2003

United Therapeutics Corporation

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other
Jurisdiction of
Incorporation)

000-26301

(Commission
File Number)

52-1984749

(I.R.S. Employer
Identification Number)

1110 Spring Street
Silver Spring, MD

(Address of Principal Executive Offices)

20910

(Zip Code)

Registrant's telephone number, including area code:

(301) 608-9292

Item 5. Other Events.

On May 13, 2003, United Therapeutics Corporation (the Company) issued a press release, a copy of which is attached as Exhibit 99.1, announcing that Roger Jeffs, Ph.D., its President and Chief Operating Officer, has adopted a prearranged trading plan in accordance with Securities and Exchange Commission Rule 10b5-1.

Item 7. Exhibits

(c) Exhibits

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press release dated May 13, 2003

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

UNITED THERAPEUTICS CORPORATION

Dated: May 13, 2003

By: /s/ Paul A. Mahon

Name: Paul A. Mahon
Title: SVP and General Counsel

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press release dated May 13, 2003